| 1347 |
National Cancer Institute |
Html |
null |
Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of pancreatic neuroendocrine tumors (islet cell tumors). |
|
|
CLICK HERE |
| 1352 |
National Cancer Institute |
Html |
en |
Bladder Cancer Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of bladder cancer. |
| bladder infections | 0.409188 |
| cancer spreads | 0.362526 |
| body | 0.421643 |
| type | 0.363946 |
| transitional cell carcinoma | 0.368057 |
| Partial cystectomy | 0.367914 |
| following PDQ summaries | 0.361033 |
| PDQ cancer information | 0.437047 |
| cancer increases | 0.35829 |
| clinical trial search | 0.428286 |
| bladder cancer | 0.996648 |
| clinical trials | 0.716737 |
| stage IV bladder | 0.400568 |
| cancer information summary | 0.412718 |
| clinical trial | 0.562865 |
| Institute about bladder | 0.388854 |
| breast cancer prevention | 0.364729 |
| superficial bladder cancer | 0.471082 |
| patients | 0.385176 |
| treatment clinical trial | 0.370642 |
| PDQ Adult Treatment | 0.359776 |
| NCI PDQ cancer | 0.382156 |
| lymph nodes | 0.358627 |
| radiation therapy | 0.477016 |
| Treatment Editorial Board | 0.366853 |
|
| metastatic bladder cancer | 0.451959 |
| General information | 0.370997 |
| general cancer information | 0.374576 |
| treatment | 0.542299 |
| cancer prevention | 0.364857 |
| new cancer treatments | 0.373348 |
| Recurrent bladder cancer | 0.48553 |
| NCI-supported cancer | 0.389073 |
| Cancer Information Service | 0.375145 |
| urinary diversion | 0.368656 |
| invasive bladder cancer | 0.467339 |
| treatment clinical trials | 0.395244 |
| National Cancer Institute | 0.448421 |
| radical cystectomy | 0.396674 |
| new treatment | 0.433088 |
| External radiation therapy | 0.441508 |
| Bladder Cancer Treatment | 0.456321 |
| Cancer Care page | 0.36454 |
| Blood. The cancer | 0.364373 |
| bladder cancer cells | 0.466875 |
| cancer research process | 0.367381 |
| cancer clinical trials | 0.446025 |
| cancer information summaries | 0.373713 |
| comprehensive cancer information | 0.373405 |
|
CLICK HERE |
| 1690 |
National Cancer Institute |
Html |
en |
Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of pheochromocytoma and paraganglioma. |
| cancer treatment | 0.520384 |
| malignant tumor cells | 0.51392 |
| inherited pheochromocytoma | 0.499674 |
| metastatic pheochromocytoma | 0.559666 |
| catecholamine levels | 0.546812 |
| recurrent pheochromocytoma | 0.523941 |
| body | 0.55921 |
| PDQ cancer information | 0.583541 |
| clinical trial search | 0.545652 |
| clinical trials | 0.955841 |
| adrenal gland | 0.817016 |
| cancer information summary | 0.547255 |
| clinical trial | 0.684878 |
| blood pressure | 0.689096 |
| entire adrenal gland | 0.501423 |
| detailed pictures | 0.500985 |
| patients | 0.570303 |
| pheochromocytoma | 0.843137 |
| blood vessels | 0.513601 |
| PDQ Pheochromocytoma | 0.514265 |
| NCI PDQ cancer | 0.498564 |
| lymph nodes | 0.51055 |
| radiation therapy | 0.504762 |
| tyrosine kinase inhibitor | 0.539116 |
|
| benign pheochromocytoma | 0.496121 |
| treatment | 0.708415 |
| general information | 0.506946 |
| magnetic resonance imaging | 0.497402 |
| cancer cells | 0.57041 |
| adrenal cortex | 0.501382 |
| adrenal medulla | 0.501576 |
| multiple endocrine neoplasia | 0.503339 |
| treatment clinical trials | 0.532049 |
| National Cancer Institute | 0.548616 |
| tumor cells | 0.524483 |
| new treatment | 0.564593 |
| heart rate | 0.509798 |
| pheochromocytoma spreads | 0.501294 |
| pheochromocytoma cells | 0.532172 |
| Pheochromocytoma forms | 0.519073 |
| adrenal glands | 0.85433 |
| nuclear magnetic resonance | 0.499251 |
| paraganglioma | 0.578972 |
| tumors | 0.523973 |
| cancer clinical trials | 0.561663 |
| high blood pressure | 0.675166 |
| tumor | 0.650897 |
| cancer | 0.88724 |
|
CLICK HERE |
| 1715 |
National Cancer Institute |
Html |
en |
Tests to Detect Colorectal Cancer and Polyps |
A fact sheet that discusses the advantages and disadvantages of several colorectal cancer screening tests. |
| standard colonoscopy | 0.642704 |
| average risk | 0.571434 |
| sigmoidoscopy screening | 0.568313 |
| entire colon | 0.614214 |
| colorectal polyps | 0.605561 |
| abnormal growths | 0.57234 |
| colon problems | 0.570159 |
| Occult Blood Test | 0.556564 |
| early-stage colorectal cancer | 0.600935 |
| occult blood tests | 0.564372 |
| thorough cleansing | 0.581775 |
| asymptomatic colorectal cancer | 0.60263 |
| flexible lighted tube | 0.561607 |
| colorectal cancer screening | 0.734621 |
| flexible sigmoidoscopy screening | 0.562785 |
| small polyps | 0.567222 |
| digital rectal examination | 0.560544 |
| polyps | 0.617192 |
| colorectal cancer | 0.956004 |
| test | 0.736074 |
| new colorectal cancer | 0.625336 |
| guaiac FOBT | 0.612613 |
| single-specimen guaiac fobt | 0.570386 |
| inflammatory bowel disease | 0.568257 |
| ) colonoscopy. | 0.566733 |
|
| colon cancer incidence | 0.618181 |
| acceptable screening tests | 0.563922 |
| fecal occult blood | 0.636365 |
| colorectal cancers | 0.601521 |
| rectum | 0.592026 |
| colon tissue | 0.560628 |
| lower colon | 0.576523 |
| colon cancer mortality | 0.592993 |
| United States | 0.573668 |
| Additional procedures | 0.566333 |
| colonoscopy screening methods | 0.603294 |
| False-positive test results | 0.579985 |
| stool sample | 0.563739 |
| colorectal cancer incidence | 0.613064 |
| colon cancer | 0.621651 |
| fecal immunochemical test | 0.563508 |
| stool dna test | 0.61197 |
| people | 0.593294 |
| virtual colonoscopy | 0.697133 |
| cancer screening tests | 0.581698 |
| family history | 0.558032 |
| sigmoid colon | 0.589237 |
| colon | 0.791161 |
| et al | 0.626521 |
|
CLICK HERE |
| 1940 |
National Cancer Institute |
Html |
es |
La espiritualidad en el tratamiento del cáncer (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca de la influencia que tiene la espiritualidad y la religión en las personas que tienen cáncer. Se discuten varios métodos sobre manejo e intervención. |
| enfermos ayuda | 0.452293 |
| La espiritualidad | 0.924579 |
| términos espiritualidad | 0.486044 |
| siguientes aspectos | 0.444194 |
| Physician Data Query | 0.534722 |
|
| National Cancer Institute | 0.427034 |
| siguientes riesgos | 0.41834 |
| libre uso | 0.416111 |
| siguientes maneras | 0.524006 |
| Instituto Nacional | 0.45946 |
|
CLICK HERE |
| 2076 |
National Cancer Institute |
Html |
es |
Alcohol y el riesgo de cáncer |
Hoja informativa que resume la comprobación de la relación entre el consumo de alcohol y el riesgo de varios cánceres. Incluye información de los factores que afectan el riesgo de cánceres asociados con el alcohol, como son los genes y el uso de tabaco. |
| Neck Cancer Epidemiology | 0.538614 |
| Lancet Oncology | 0.534891 |
| Hirose K | 0.511352 |
| Matsuo K | 0.510531 |
| levadura fermenta azúcares | 0.523222 |
| pharyngeal cancers | 0.510877 |
| Alcohol drinking cessation | 0.626157 |
| British Journal | 0.511017 |
| vitamina a | 0.51094 |
| Straif K | 0.510855 |
| vitamina e | 0.511443 |
| IARC Monographs | 0.512402 |
| IARC Working Group | 0.518509 |
| riesgos resultantes | 0.517271 |
| Estados Unidos | 0.591854 |
| alcohol drinking | 0.759868 |
| Tajima K | 0.511125 |
| PubMed Abstract | 0.957874 |
| neck cancers | 0.610459 |
| Cancer Epidemiology | 0.551257 |
| Beral V | 0.510723 |
| Liver Disease | 0.511887 |
| cancer prevention | 0.54975 |
| alcohol consumption with | 0.621668 |
| vino tinto | 0.531211 |
|
| results from subgroup | 0.518268 |
| International Head | 0.510721 |
| Fedirko V | 0.510662 |
| contaminantes cancerÃgenos | 0.510849 |
| Carcinogenic Risks | 0.530612 |
| ADH hiperactiva | 0.535244 |
| Numerosos estudios | 0.516257 |
| preclinical studies | 0.511192 |
| enzima hiperactiva | 0.522144 |
| Bonifazi M | 0.510536 |
| epidemiological studies | 0.512501 |
| Hodgkin lymphoma | 0.511109 |
| enzima adh hiperactiva | 0.532963 |
| Tramacere I | 0.552596 |
| genetic polymorphisms | 0.530043 |
| enzima llamada | 0.519065 |
| Bagnardi V | 0.51066 |
| Rehm J | 0.529488 |
| cabo estudios | 0.515059 |
| pooled analysis | 0.527827 |
| renal cell carcinoma | 0.521274 |
| Cancer Institute | 0.525901 |
| células renales | 0.53114 |
| New York Academy | 0.514614 |
|
CLICK HERE |
| 3712 |
National Cancer Institute |
Html |
en |
Understanding Precision Medicine in Cancer Treatment |
Precision medicine helps doctors select cancer treatments that are most likely to help patients based on a genetic understanding of their disease. Learn about the promise of precision medicine and the role it plays in cancer treatment. |
| cancer treatment | 0.440203 |
| routine care | 0.360336 |
| tumor profiling | 0.359671 |
| medicine clinical trials | 0.414587 |
| type | 0.382285 |
| specific change | 0.357217 |
| new treatments | 0.362099 |
| treatments | 0.484331 |
| research | 0.393932 |
| open trials | 0.357639 |
| rectal cancers | 0.362107 |
| Targeted Cancer Therapies | 0.436947 |
| clinical trials | 0.515013 |
| cancer-causing genetic changes | 0.439486 |
| precision medicine approach | 0.418811 |
| additional genetic changes | 0.428246 |
| cancer-causing changes | 0.378722 |
| researchers | 0.363172 |
| patients | 0.398147 |
| trial staff | 0.356601 |
| cancer types | 0.375159 |
| patient care | 0.366351 |
| different types | 0.361116 |
| Tumor DNA Sequencing | 0.40382 |
| radiation therapy | 0.360769 |
|
| precision medicine | 0.96121 |
| person’s cancer | 0.378533 |
| genetic tests | 0.37503 |
| treatment | 0.491183 |
| precision medicine trials | 0.417382 |
| United States | 0.359831 |
| Cancer Information Service | 0.419259 |
| special lab | 0.36045 |
| targeted drug | 0.368994 |
| genetic understanding | 0.381915 |
| consent form | 0.358985 |
| different people | 0.367337 |
| Research studies | 0.361413 |
| molecular profiling | 0.357183 |
| drugs | 0.382294 |
| specific genetic changes | 0.430567 |
| certain genetic changes | 0.427035 |
| Targeted Therapy | 0.372422 |
| recent advances | 0.370536 |
| genetic changes | 0.967087 |
| specific types | 0.356978 |
| medicine clinical trial | 0.490589 |
| search tool | 0.359567 |
| cancer | 0.783975 |
|
CLICK HERE |
| 16567 |
National Cancer Institute |
Html |
en |
Pembrolizumab Improves Survival for Some Patients with Advanced Non-Small Cell Lung Cancer |
A summary of clinical trial results showing that pembrolizumab improved progression-free and overall survival for patients with advanced non-small cell lung cancer. |
| platinum-based chemotherapy | 0.628936 |
| PD-L1 positive tumors | 0.620887 |
| advanced non-small cell | 0.629259 |
| PD-L1 expression | 0.628117 |
| 1-year overall survival | 0.61848 |
| higher progression-free survival | 0.617259 |
| chemotherapy | 0.698592 |
| time patients | 0.588415 |
| chemotherapy group | 0.668963 |
| immune-mediated adverse events | 0.635601 |
| Dana-Farber Cancer Institute | 0.607312 |
| lung cancer | 0.570765 |
| biomarker. Earlier trials | 0.611797 |
| PD-L1 IHC 22C3 | 0.643265 |
| immune response | 0.572023 |
| PD-L1 protein present | 0.63991 |
| overall survival | 0.629887 |
| immune-mediated deaths | 0.578857 |
| National Cancer Institute | 0.604313 |
| tumor cells | 0.913581 |
| randomized phase | 0.574689 |
| median progression-free survival | 0.633329 |
| PD-L1-expressing tumor cells | 0.661448 |
| immune therapy | 0.577956 |
|
| immune-mediated events | 0.578589 |
| progression-free survival | 0.757999 |
| pembrolizumab group | 0.672943 |
| platinum-based doublet chemotherapy | 0.672126 |
| standard chemotherapy | 0.609699 |
| phase III CheckMate | 0.569846 |
| patients | 0.63251 |
| trial results | 0.620704 |
| previously treated patients | 0.61738 |
| immune cells | 0.61252 |
| adverse events | 0.670445 |
| Dr. Malik | 0.709776 |
| earlier phase trial | 0.627214 |
| metastatic NSCLC | 0.599852 |
| Bruce E. Johnson | 0.59961 |
| survival advantage | 0.568599 |
| untreated advanced NSCLC | 0.642891 |
| New England Journal | 0.615224 |
| severe skin reactions | 0.605442 |
| checkpoint inhibitor pembrolizumab | 0.658193 |
| phase III trial | 0.569107 |
| Pembrolizumab blocks PD-1 | 0.629649 |
| Shakun Malik | 0.582607 |
|
CLICK HERE |
| 17277 |
National Cancer Institute |
Html |
null |
Cáncer avanzado y quienes cuidan |
Si usted cuida a un paciente, puede sentir cansancio y preocupación a medida que se enfrenta al cáncer de su ser querido. Cuidar a alguien con cáncer avanzado trae desafíos y preocupaciones nuevas. |
|
|
CLICK HERE |
| 17288 |
National Cancer Institute |
Html |
es |
Personal de atención para la salud |
Información sobre el equipo de tratamiento de proveedores de salud que trabajan juntos para ayudar a pacientes con cáncer. |
| cuáles alimentos | 0.989407 |
|
|
CLICK HERE |